Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity

BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Arthritis Res Ther
Autores principales: Ikeda, Tomoko, Fujii, Hiroshi, Nose, Masato, Kamogawa, Yukiko, Shirai, Tsuyoshi, Shirota, Yuko, Ishii, Tomonori, Harigae, Hideo
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/
https://ncbi.nlm.nih.gov/pubmed/28800777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares